Download full-text PDF |
Source |
---|
Dermatopathology (Basel)
July 2024
Department of Anatomic Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Int J Surg Case Rep
July 2024
Damascus university, Faculty of Medicine, Damascus, Syrian Arab Republic; Stemosis for Scientific Research, Damascus, Syrian Arab Republic.
Cancers (Basel)
April 2024
Department of Dermatology and Allergy, LMU University Hospital, LMU Munich, 80337 Munich, Germany.
Virchows Arch
May 2024
Department of Pathology, Massachusetts General Hospital and Harvard Medical School, WRN2, 55 Fruit St, Boston, MA, 02114, USA.
Diagnosis of desmoid-type fibromatosis (DF) may be challenging on biopsy due to morphologic overlap with reactive fibrosis (scar) and other uniform spindle cell neoplasms. Evaluation of nuclear β-catenin, a surrogate of Wnt pathway activation, is often difficult in DF due to weak nuclear expression and high background membranous/cytoplasmic staining. Lymphoid enhancer-factor 1 (LEF1) is a recently characterized effector partner of β-catenin which activates the transcription of target genes.
View Article and Find Full Text PDFIndian J Otolaryngol Head Neck Surg
February 2024
K.D. Parvadiya Multispeciality Hospital, Atkot, Gujarat 360040 India.
Dermatofibroma is a commonly occurring cutaneous entity usually centered within the skin's dermis. Dermatofibromas are referred to as benign fibrous histiocytomas of the skin, superficial/cutaneous benign fibrous histiocytomas, or common fibrous histiocytoma. These mesenchymal cell lesions of the dermis clinically are firm subcutaneous nodules that occur on the extremities in the vast majority of cases and may or may not be associated with overlying skin changes.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!